DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Antiviral are 317

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0056	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0057	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0058	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0059	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0060	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0061	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0062	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0063	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0064	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0065	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0247	Celgosivir	Antiviral	Hepatitis C virus	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.52 ± 0.21 Ct)	Investigational	27801778
DrugRepV_0248	Celgosivir	Antiviral	Hepatitis C virus	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.41 ± 0.12 Ct)	Investigational	27801778
DrugRepV_0249	Castanospermine	Antiviral	Dengue and Parainfluenza	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?1.58 ± 3.23 Ct)	Experimental	27801778
DrugRepV_0250	Castanospermine	Antiviral	Dengue and Parainfluenza	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?0.26 ± 4.11 Ct)	Experimental	27801778
DrugRepV_0744	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Malaysia	NA	Plaque assay	Decrease (50 %)	Investigational	29765101
DrugRepV_0745	Favipiravir	Antiviral	Influenza virus	Hendra virus	Prototype	NA	Plaque assay	Decrease (50 %)	Investigational	29765101
DrugRepV_0746	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Bangladesh	NA	Plaque assay	Decrease (50 %)	Investigational	29765101
DrugRepV_0747	Favipiravir	Antiviral	Influenza virus	Nipah virus	rNiV-Gluc-eGFP	NA	Plaque assay	Decrease (50 %)	Investigational	29765101
DrugRepV_0748	Favipiravir	Antiviral	Influenza virus	Nipah virus	rNiV-Gluc-eGFP	NA	Cytopathic effect (CPE) assay	Decrease (4 Log (pfu/ml))	Investigational	29765101
DrugRepV_0749	Favipiravir	Antiviral	Influenza virus	Nipah virus	rNiV-Gluc-eGFP	NA	Real-time PCR	Decrease (10 Fold)	Investigational	29765101
DrugRepV_0750	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Malaysia	NA	NA	Increase	Investigational	29765101
DrugRepV_0751	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Malaysia	NA	Real-time PCR	Decrease (20,000 / 2,000 / 500 Fold)	Investigational	29765101
DrugRepV_0752	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Malaysia	NA	Immunohistochemical assay	Decrease	Investigational	29765101
DrugRepV_0753	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Malaysia	NA	Survival assay	Increase	Investigational	29765101
DrugRepV_0754	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Malaysia	NA	Real-time PCR	Decrease (30,000 / 300 / 100 Fold)	Investigational	29765101
DrugRepV_0755	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Malaysia	NA	Immunohistochemical assay	Decrease	Investigational	29765101
DrugRepV_0756	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Increase (7 %)	Investigational	26930627
DrugRepV_0757	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	Real-time PCR	No significant effect	Investigational	26930627
DrugRepV_0758	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Decrease (33 %)	Investigational	26930627
DrugRepV_0759	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	Real-time PCR	Decrease	Investigational	26930627
DrugRepV_1620	Palmitoylethanolamide	Antiviral	Respiratory viral infection	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Experimental	24991006
DrugRepV_2107	NITD008	Antiviral	NA	Zika virus	GZ01/2016	NA	Plaque assay	Decrease (50 %)	NA	27747251
DrugRepV_2108	NITD008	Antiviral	NA	Zika virus	FSS13025/2010	NA	Plaque assay	Decrease (50 %)	NA	27747251
DrugRepV_2109	NITD008	Antiviral	NA	Zika virus	GZ01/2016	NA	Real-time PCR	Decrease (50 %)	NA	27747251
DrugRepV_2110	NITD008	Antiviral	NA	Zika virus	FSS13025/2010	NA	Real-time PCR	Decrease (50 %)	NA	27747251
DrugRepV_2111	NITD008	Antiviral	NA	Zika virus	GZ01/2016	NA	Survival assay	Increase	NA	27747251
DrugRepV_2112	NITD008	Antiviral	NA	Zika virus	GZ01/2016	NA	Real-time PCR	Decrease (2.6 Fold)	NA	27747251
DrugRepV_2130	Favipiravir	Antiviral	Influenza virus	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27163257
DrugRepV_2131	Favipiravir	Antiviral	Influenza virus	Zika virus	MR766	NA	Virus yield reduction assay	Decrease (50 %)	Investigational	27163257
DrugRepV_2875	Peramivir Trihydrate	Antiviral	Influenza A/B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.0856963 %)	Approved	27742486
DrugRepV_3234	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Indian Ocean strain 899	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3235	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Indian Ocean strain 899	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3236	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	LR2006 OPY1	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3237	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	LR2006 OPY1	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3238	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Italy 2008 (clinical)	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3239	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Italy 2008 (clinical)	NA	Colorimetric method	Decrease (50 %)	Investigational	24951535
DrugRepV_3242	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Indian Ocean strain 899	NA	Real-time PCR	Decrease (50 %)	Investigational	24951535
DrugRepV_3243	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Indian Ocean strain 899	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3244	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	LR2006 OPY1	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3245	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Venturini (Italy 2008)	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3246	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Bianchi (Italy 2008)	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3247	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Congo 95 (2011)	NA	Plaque assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3254	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV 899	NA	Real-time PCR	Decrease (95 %)	Investigational	24951535
DrugRepV_3255	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV 899	NA	Real-time PCR	Decrease (98 %)	Investigational	24951535
DrugRepV_3256	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV 899	NA	Real-time PCR	Decrease (88 %)	Investigational	24951535
DrugRepV_3257	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV S27	NA	Survival assay	NA	Investigational	24951535
DrugRepV_3258	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV S27	NA	Survival assay	NA	Investigational	24951535
DrugRepV_3259	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV S27	NA	Real-time PCR	Decrease (3.2 ± 0.1 Log)	Investigational	24951535
DrugRepV_3260	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	CHIKV S27	NA	Real-time PCR	Decrease (2.3 ± 0.3 Log)	Investigational	24951535
DrugRepV_3261	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3262	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3263	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3267	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res_p7 C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3268	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res_p7 C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3269	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	Favipiravir_res_p7 C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	24951535
DrugRepV_3520	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/Ohio/88/2012		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3521	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/Ohio/83/2012		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3522	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/Washington/01/2007		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3523	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/Texas/12/2007		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3524	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/California/04/2009		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3525	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/Ohio/88/2012		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3526	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/Ohio/83/2012		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3527	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/Washington/01/2007		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3528	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/Texas/12/2007		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3529	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/California/04/2009		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3560	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Investigational	30354193
DrugRepV_3561	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Investigational	30354193
DrugRepV_3562	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Investigational	30354193
DrugRepV_3860	Favipiravir	Antiviral	Influenza virus	Marburg virus	Leiden	NA	RT-PCR	Decrease (50 %)	Investigational	27736754
DrugRepV_3861	Favipiravir	Antiviral	Influenza virus	Rift Valley fever virus	MP12	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27736754
DrugRepV_3862	Favipiravir	Antiviral	Influenza virus	Lassa virus	Ba366	NA	NA	Decrease (50 %)	Investigational	27736754
DrugRepV_3863	Favipiravir	Antiviral	Influenza virus	Lassa virus	Josiah	NA	Immunohistochemical assay	Decrease (50 %)	Investigational	27736754
DrugRepV_3864	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	Afg-09 2990	NA	MTT assay	Decrease (50 %)	Investigational	27736754
DrugRepV_3865	Favipiravir	Antiviral	Influenza virus	Ebola virus	Mayinga 1976	NA	MTT assay	Decrease (50 %)	Investigational	27736754
DrugRepV_3866	Favipiravir	Antiviral	Influenza virus	Ebola virus	Kikwit 1995/E718	NA	NA	Decrease (50 %)	Investigational	27736754
DrugRepV_3935	Favipiravir	Antiviral	Influenza virus	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	Investigational	29289664
DrugRepV_3936	Favipiravir	Antiviral	Influenza virus	Ebola virus	Makona	NA	NA	Decrease (50 %)	Investigational	29289664
DrugRepV_3937	Favipiravir	Antiviral	Influenza virus	Marburg virus	Ci67	NA	NA	Decrease (50 %)	Investigational	29289664
DrugRepV_3951	Favipiravir	Antiviral	Influenza virus	Marburg virus	NA	NA	qRT-PCR	Decrease (50 %)	Investigational	29369776
DrugRepV_3952	Favipiravir	Antiviral	Influenza virus	Marburg virus	NA	NA	qRT-PCR	Decrease	Investigational	29369776
DrugRepV_4185	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	SL10571	NA	MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_4187	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	S27	NA	MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_4189	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	BaH306	NA	MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_4471	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4472	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-Gluc	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4473	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4474	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4475	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4476	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4477	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4478	Brincidofovir	Antiviral	Viral infections	Ebola virus	Mayinga	NA	Operetta High Content Imaging System	Decrease (50 %)	Investigational	26526586
DrugRepV_4479	Brincidofovir	Antiviral	Viral infections	Ebola virus	Makona	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4480	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Kikwit	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4481	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Kikwit	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4482	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Kikwit	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4483	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Makona	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4484	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Makona	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4485	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Makona	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4512	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Increase	Investigational	30275474
DrugRepV_4513	Remdesivir	Antiviral	Hepatitis C | Ebola	Ebola virus	NA	NA	NA	Increase	Experimental	30275474
DrugRepV_4514	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Increase	Investigational	29584730
DrugRepV_4650	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Investigational	28098253
DrugRepV_4683	NITD008	Antiviral	NA	Zika virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	29288699
DrugRepV_5072	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	10200	NA	NA	Decrease (50 %)	Investigational	29936152
DrugRepV_5073	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	Hoti	NA	NA	Decrease (50 %)	Investigational	29936152
DrugRepV_5074	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	10200	NA	Survival assay	Increase	Investigational	29936152
DrugRepV_5075	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	Hoti	NA	Survival assay	Increase	Investigational	29936152
DrugRepV_5076	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	10200	NA	Real-time PCR	Decrease	Investigational	29936152
DrugRepV_5077	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	Hoti	NA	Real-time PCR	Decrease	Investigational	29936152
DrugRepV_5092	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Western blot	Decrease	Investigational	16372299
DrugRepV_5093	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Western blot	Decrease	Investigational	16372299
DrugRepV_5094	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Fluorescence-based assay	Decrease (3 log FFU/ml)	Investigational	16372299
DrugRepV_5095	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Fluorescence-based assay	No significant effect (2 fold FFU/ml)	Investigational	16372299
DrugRepV_5096	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Real-time PCR	Decrease	Investigational	16372299
DrugRepV_5097	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Real-time PCR	No significant effect	Investigational	16372299
DrugRepV_5099	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	29024765
DrugRepV_5121	Balapiravir	Antiviral	Viral infection (Dengue and Hepatitis C, Chronic)	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (7 %)	Investigational	29024765
DrugRepV_5128	NITD008	Antiviral	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-23 %)	NA	29024765
DrugRepV_5134	R-7128	Antiviral	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-1 %)	Investigational	29024765
DrugRepV_5138	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (88 %)	Investigational	29024765
DrugRepV_5206	Favipiravir	Antiviral	Influenza virus	Rift Valley fever virus	ZH501	NA	Survival assay	Increase	Investigational	24722586
DrugRepV_5207	Favipiravir	Antiviral	Influenza virus	Rift Valley fever virus	ZH501	NA	Plaque assay	Decrease	Investigational	24722586
DrugRepV_5269	Favipiravir	Antiviral	Influenza virus	Lassa virus	Josiah	NA	TCID50 assay	Decrease (90 %)	Investigational	26456301
DrugRepV_5270	Favipiravir	Antiviral	Influenza virus	Lassa virus	Josiah	NA	TCID50 assay	Decrease (90 %)	Investigational	26456301
DrugRepV_5271	Favipiravir	Antiviral	Influenza virus	Lassa virus	Josiah	NA	Survival assay	Increase	Investigational	26456301
DrugRepV_5272	Favipiravir	Antiviral	Influenza virus	Lassa virus	Josiah	NA	Survival assay	Increase	Investigational	26456301
DrugRepV_5473	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Experimental	32020029
DrugRepV_5478	Favipiravir	Antiviral	Influenza virus	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Investigational	32020029
DrugRepV_5636	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5637	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5638	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5639	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5640	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5641	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5642	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5643	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5644	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5645	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5646	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5647	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5648	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		NA	Increase	Phase II	26794905
DrugRepV_5649	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		NA	Increase	Phase II	26794905
DrugRepV_5650	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		NA	Increase	Phase II	26794905
DrugRepV_5651	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Real-time PCR	Decrease (4.3 Fold)	Phase II	26794905
DrugRepV_5652	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Real-time PCR	Decrease (16.5 Fold)	Phase II	26794905
DrugRepV_5653	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Real-time PCR	Decrease (2.4 Fold)	Phase II	26794905
DrugRepV_5654	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Real-time PCR	Decrease (0.5 Log (copies/ml))	Phase II	26794905
DrugRepV_5655	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Real-time PCR	Decrease (2 Log (copies/ml))	Phase II	26794905
DrugRepV_5677	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Thsman		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5678	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	FR37 -clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5679	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	FR42-clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5680	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	FR28 -clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5681	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	FR34 -clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5682	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Th36		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5683	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	32/0140 --clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5684	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	32/0102--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5685	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0178--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5686	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0051--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5687	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	H87		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5688	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0072--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5689	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0253--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5690	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0177--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5691	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0096--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5692	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	H241		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5693	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Phili/1567- patient strain as gift		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5694	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Venz/JQ - patient strain as gift		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5695	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Senga/DA - patient strain as gift		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5696	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	NA		Real-time PCR	Increase (0.2 Log10 Copies/ml)	Phase II failed	22807519
DrugRepV_5697	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	NA		Real-time PCR	Increase (0.5 Log10 Copies/ml)	Phase II failed	22807519
DrugRepV_5698	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	NA		Real-time PCR	No significant effect (0.7 Log10 Copies/ml)	Phase II failed	22807519
DrugRepV_5699	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	NA		Real-time PCR	Increase (0.3 Log10 Copies/ml)	Phase II failed	22807519
DrugRepV_5707	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	TSV01		Plaque assay	No significant effect (<0.5 Log10 PFU/ml)	Phase II failed	24257621
DrugRepV_5948	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_5949	NITD008	Antiviral	NA	Dengue virus	Hawaii		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5950	NITD008	Antiviral	NA	Dengue virus	MY10245		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5951	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5952	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_5953	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19918064
DrugRepV_5954	NITD008	Antiviral	NA	Dengue virus	MY21531		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5955	NITD008	Antiviral	NA	Dengue virus	MY22366		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5956	NITD008	Antiviral	NA	Dengue virus	MY22713		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5957	NITD008	Antiviral	NA	Dengue virus	MY10245		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5958	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5959	NITD008	Antiviral	NA	Dengue virus	MY10340		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5960	NITD008	Antiviral	NA	Dengue virus	MY21531		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5961	NITD008	Antiviral	NA	Dengue virus	MY22366		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5962	NITD008	Antiviral	NA	Dengue virus	MY22713		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5963	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19918064
DrugRepV_5964	NITD008	Antiviral	NA	Dengue virus	MY10245		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_5965	NITD008	Antiviral	NA	Dengue virus	D2S10		Survival assay	Increase	NA	19918064
DrugRepV_5966	NITD008	Antiviral	NA	Dengue virus	D2S10		Plaque assay	Decrease (6.4 Fold)	NA	19918064
DrugRepV_5967	NITD008	Antiviral	NA	Dengue virus	TS01		Plaque assay	Decrease (10 Fold)	NA	19918064
DrugRepV_5968	NITD008	Antiviral	NA	Dengue virus	TS01		Enzyme-linked immunosorbent assay	Decrease (6 Fold)	NA	19918064
DrugRepV_5974	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	FGA/89		Focus immunoassay	Decrease (95 %)	Experimental	10590151
DrugRepV_5976	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681		Plaque assay	Decrease (50 %)	Experimental	15994763
DrugRepV_5977	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681		Plaque assay	Decrease (50 %)	Experimental	15994763
DrugRepV_5978	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681		Western blot	Decrease	Experimental	15994763
DrugRepV_5979	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5980	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5981	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5982	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5983	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Flow cytometry	Decrease	Experimental	15994763
DrugRepV_5984	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Flow cytometry	Decrease	Experimental	15994763
DrugRepV_5985	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Flow cytometry	Decrease	Experimental	15994763
DrugRepV_5986	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Flow cytometry	Decrease	Experimental	15994763
DrugRepV_5987	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681-Replicon		Renilla luciferase assay	Decrease	Experimental	15994763
DrugRepV_5988	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (>50 %)	Phase II	22867971
DrugRepV_5989	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Survival assay	Decrease	Phase II	22867971
DrugRepV_5990	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	NA		Plaque assay	No significant difference	Phase II	27509020
DrugRepV_6115	Favipiravir	Antiviral	Influenza virus	Dengue virus	hu/PHL/10-07		MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_6116	Favipiravir	Antiviral	Influenza virus	Dengue virus	hu/INDIA/09–74		MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_6129	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Dengue virus	New Guinea C		NA	Decrease (50 %)	Investigational	29890736
DrugRepV_6136	Favipiravir	Antiviral	Influenza virus	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	Investigational	29672522
DrugRepV_6478	Castanospermine	Antiviral	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	Experimental	17354651
DrugRepV_6510	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6514	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6518	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6522	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6526	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6530	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6534	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6610	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6611	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6612	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6613	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6614	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6615	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6616	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6617	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6618	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6619	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6620	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6668	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6669	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6670	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6671	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6672	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6673	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6674	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6675	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6676	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6677	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6678	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6679	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6728	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6729	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6730	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6731	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6732	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6733	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6734	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6735	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6736	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6737	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6738	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6739	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6770	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6771	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6772	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6773	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6774	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6775	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6803	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6804	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6805	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6806	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6807	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6808	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6809	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6829	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6830	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6831	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6832	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6855	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6856	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6857	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6858	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6859	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6860	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_7090	NITD008	Antiviral	NA	West Nile virus	New York 3356		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_7091	NITD008	Antiviral	NA	Yellow fever virus	17D vaccine strain		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_7092	Castanospermine	Antiviral	Dengue and Parainfluenza	West Nile virus	NY 1999-Replicon		Renilla luciferase assay	No significant difference	Experimental	15994763
DrugRepV_7093	Castanospermine	Antiviral	Dengue and Parainfluenza	West Nile virus	NY 1999-Replicon		Survival assay	Increase	Experimental	15994763
DrugRepV_7094	Castanospermine	Antiviral	Dengue and Parainfluenza	West Nile virus	NY 1999-Replicon		Survival assay	No significant difference	Experimental	15994763
DrugRepV_7241	Favipiravir	Antiviral	Influenza virus	Yellow fever virus	17D		Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27736754
DrugRepV_7317	NITD008	Antiviral	NA	Japanese encephalitis virus	JEV?Pac?Rluc?Rep		Luciferase assay	Decrease (50 %)	NA	28779235
DrugRepV_7318	NITD008	Antiviral	NA	Japanese encephalitis virus	JEV?Pac?Rluc?Rep		Western blot	Decrease (NA %)	NA	28779235
DrugRepV_7425	Castanospermine	Antiviral	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	Experimental	17354651
DrugRepV_7548	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Experimental	32438446
DrugRepV_7549	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Experimental	32438446
DrugRepV_7554	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (50 %)	Experimental	32438446
DrugRepV_7555	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (90 %)	Experimental	32438446
DrugRepV_7617	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	SARS-CoV-2 (?CoV/KOR/KCDC03/2020	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	32438446
DrugRepV_7639	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	?CoV/KOR/KCDC03/2019	NA	Immunofluorescence	Decrease (50 %)	Experimental	32438446
DrugRepV_7640	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	?CoV/KOR/KCDC03/2019	NA	Immunofluorescence	Decrease (90 %)	Experimental	32438446
DrugRepV_7649	Favipiravir	Antiviral	Influenza virus	SARS Coronavirus-2	Wuhan/WIV04/2019	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Investigational	32438446
DrugRepV_7650	Favipiravir	Antiviral	Influenza virus	SARS Coronavirus-2	Wuhan/WIV04/2019	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Investigational	32438446
DrugRepV_7689	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Experimental	32577649
DrugRepV_7709	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	NA	NA	Plaque reduction assay	Decrease (50 %)	Experimental	32532085
DrugRepV_7723	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Experimental	32707573
DrugRepV_7735	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Experimental	32707573
DrugRepV_7747	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Experimental	32707573
DrugRepV_7771	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Experimental	32687696
DrugRepV_7772	Favipiravir	Antiviral	Influenza virus	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32687696
DrugRepV_7784	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	NA	NA	LC-MS/MS	Decrease (50 %)	Experimental	32589775
DrugRepV_7785	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	NA	NA	LC-MS/MS	Decrease (50 %)	Experimental	32589775
DrugRepV_8325	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	32429580